http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Strategies to mitigate the toxicity of cancer therapeutics
Strategies to Mitigate the Toxicity of Cancer Therapeutics, Volume 155 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters, each of which is written by an international board of authors.- Provides the authority and expertise of leading contributors.
Intro -- Strategies to Mitigate the Toxicity of Cancer Therapeutics -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: An overview of chemotoxicity and radiation toxicity in cancer therapy -- 1. Introduction -- 2. Cardiotoxicity -- 3. Pulmonary toxicity -- 4. Renal toxicity -- 5. Gastrointestinal toxicity -- 5.1. Chemotherapy-induced nausea and vomiting (CINV) -- 5.2. Severe delayed onset diarrhea -- 5.3. Mucositis -- 6. Neuromuscular toxicity -- 6.1. Chemotherapy-induced peripheral neuropathy (CIPN) -- 7. Cognitive dysfunction associated with chemotherapy: ``Chemobrain or chemo fog´´ -- 8. Myalgias and arthralgias -- 9. Cutaneous toxicity -- 10. Secondary malignancies -- 11. Side effects of immune checkpoint inhibitors -- 12. Radiation therapy -- 12.1. CNS -- 12.2. Head and neck -- 12.3. Breast -- 12.4. Lung -- 12.5. Upper abdomen -- 12.6. Lower abdomen and pelvis -- 13. Mitigating/circumventing chemotoxicity -- 14. Conclusion -- References -- Chapter Two: Chemobrain: A review on mechanistic insight, targets and treatments -- 1. Introduction -- 2. Impact of chemobrain in patients -- 3. Symptoms and epidemiology -- 4. Mechanisms contributing to chemobrain -- 4.1. Oxidative stress -- 4.1.1. Occurrence of ROS and its activity -- 4.1.2. Antioxidants and their protective role -- 4.2. Absence of spinal and dendritic arborization -- 4.3. Inflammatory cytokines -- 4.4. Neurotransmitters -- 4.5. Apoptosis and autophagy -- 4.6. MAPK signalling pathway -- 4.7. Genetic factors and epigenetic modulations -- 5. Targets and treatment options -- 5.1. Targeting oxidative stress -- 5.2. Targeting neurogenesis -- 5.3. Targeting neuroinflammation -- 5.4. Targeting arborization -- 5.5. Targeting genetic factors -- 6. Current status and personalized therapy -- 7. Future perspectives -- 8. Conclusion -- Reference -- Further reading.
Chapter Three: Nephrotoxicity in cancer treatment: An update -- 1. Introduction -- 2. Risk factors for renal toxicities in cancer therapy -- 2.1. General risk factors for nephrotoxicity of anticancer drugs and treatment -- 2.2. Patient-specific factors -- 2.3. Kidney-specific factors -- 2.3.1. Genetic polymorphisms, sex and other kidney-related factors in renal enzymes -- 2.4. Drug-specific factors -- 3. Nephrotoxicity of chemotherapeutic agents and management -- 3.1. Platinum agents -- 3.1.1. Prospective use of diabetes drugs -- 3.1.2. Prospective use of antihypertensive agents -- 3.1.3. Prospective use of other clinically available drugs -- 3.1.4. Prospective targets and other compounds -- 3.2. Alkylating agents -- 3.3. Antitumor antibiotics -- 3.4. Antimetabolites cancer drugs -- 3.5. Epidermal growth factor receptor pathway inhibitors (EGFR inhibitors) -- 3.6. Vascular endothelial growth factor pathway inhibitors (VEGF inhibitors) -- 3.7. Immune checkpoint inhibitors -- 3.8. Proteasome inhibitors -- 3.9. mTOR protein kinase inhibitors -- 3.10. Biologic agents -- 3.11. BRAF inhibitors -- 3.12. Anaplastic lymphoma kinase inhibitor -- 4. Renoprotective effects of some novel anticancer therapeutics -- 4.1. The immune system -- 4.2. Sphingolipid signaling -- 4.3. DNA repair pathway -- 4.3.1. Poly(ADP-ribose) polymerase (PARP), PARP-1 -- 4.4. Histone modifications -- 4.4.1. Histone acetyltransferases (HATs) -- 4.4.2. Histone deacetylases (HDACs) -- 4.4.3. Sirtuins (SIRT) -- 4.5. Non-coding RNAs -- 5. Conclusions -- References -- Chapter Four: Chemotherapy induced gastrointestinal toxicities -- 1. Introduction -- 2. Chemotherapy-induced diarrhea -- 3. Chemotherapy-induced mucositis (CIM) -- 3.1. Intestinal epithelium -- 3.2. Pathobiological mechanisms of CIM -- 3.3. Chemotherapeutics implicated in CIM and CID -- 3.4. CIM and the microbiome.
4. Emerging mechanisms underlying chemotherapy-induced gastrointestinal toxicity -- 5. Treatment of CID -- 5.1. Current and emerging pre-clinical strategies for treating CIM -- 6. The gut and chemotherapy-induced peripheral neuropathy -- 7. Conclusion -- References -- Chapter Five: Cardiac complications of cancer therapies -- 1. Introduction -- 2. Cancer therapeutic agents -- 2.1. Anthracyclines -- 2.1.1. Mechanisms of anthracycline cardiotoxicity -- 2.1.1.1. ROS and oxidative damage -- 2.1.1.2. Topoisomerase II -- 2.1.1.3. Apoptosis -- 2.1.1.4. Ferroptosis -- 2.1.1.5. Pyroptosis -- 2.2. Tyrosine kinase inhibitors -- 2.2.1. Mechanisms of tyrosine kinase inhibitor cardiotoxicity -- 2.2.1.1. QT prolongation -- 2.2.1.2. Left ventricular dysfunction -- 2.2.1.3. Hypertension -- 2.3. Fluorouracil and other anti-metabolites -- 2.3.1. Fluorouracil and anti-metabolites induced cardiac toxicity -- 2.4. Immune therapies -- 2.4.1. IC-associated cardiotoxicities -- 2.5. Radiation therapy -- 2.5.1. Cardiotoxicity due to radiation therapy -- 2.6. Alkylating agents -- 2.6.1. Cardiotoxicity of alkylating agents -- 2.7. Platinum-based agents -- 2.7.1. Cardiotoxicity of platinum-based agents -- 2.8. Proteasome inhibitors -- 2.8.1. Cardiotoxicity from proteasome inhibitors -- 3. Current and promising therapies to prevent chemotherapy-induced cardiotoxicity -- 3.1. Dexrazoxane -- 3.2. Neurohormonal blockade -- 3.3. Statins -- 3.4. Exercise therapy -- 3.5. Remote ischemic preconditioning intervention -- 4. Conclusions -- Acknowledgments -- References -- Chapter Six: Strategies to mitigate the toxicity of cancer therapeutics -- 1. Overview of organ specific toxicities -- 2. Cancer related cognitive impairment -- 3. Ocular toxicities -- 4. Ototoxicity -- 5. Oral mucosal toxicities -- 6. Gastrointestinal toxicities -- 7. Renal toxicity.
8. Aromatase inhibitor-associated musculoskeletal syndrome -- 9. Chemotherapy induced peripheral neuropathy (CIPN) -- 10. Immunotherapy-induced autoimmunity -- 11. Putting it all together. What is the future of symptom science? -- References.
edited by David A. Gewirtz, Paul B. Fisher.
Drug-Related Side Effects and Adverse Reactions